InvestToolsWriting

Limited availabilityIndustrial in Minnesota

NexPoint Life Sciences III DST

Sponsored by NexPoint

The Offering is designed for Accredited Investors seeking to participate in a Section 1031 Exchange as well as those seeking a quality real estate investment.

NexPoint Life Sciences III DST

Offering details are for registered investors

Request access or log in to see each offering's sponsor, terms, projected distributions, photos, and documents.

Your access is being reviewed

I review every request personally and will email you as soon as your access is active. Questions? Email hello@baker1031.com.

Log in
Minimum investment
$100,000
Yr 1 distribution
4.18%
Avg distribution
4.07%
Projected hold
5–9 yrs
Offering size
$62M
Equity raise
$30.7M
Loan-to-value
50.5%
721 exit
Optional

Projected distributions by year

Capital structure

Equity
$30,661,253
Debt
$31,300,000
Total
$61,961,253

Overview

The Offering is designed for Accredited Investors seeking to participate in a Section 1031 Exchange as well as those seeking a quality real estate investment. The Sponsor is pleased to present the opportunity to invest in the Property. The Sponsor believes that the Property presents an attractive long-term investment opportunity due to strong industry tailwinds, high quality construction and infrastructure, a strong Tenant, use fundamental to the Tenant’s business as its corporate headquarters, desirable lease terms (including the 15-year initial duration of the Tenant Lease with extension options), and a strategic location.

The Property, also known as “11200 Hudson Road,” is a medical device research and development facility located at 11200 Hudson Road, Woodbury, Minnesota 55129. As of December 31, 2023, the Property was 100% leased to the Tenant.

The Tenant, Kindeva, is a global contract development and manufacturing organization (“CDMO”) in the pharmaceutical industry, focused on drug-device combination products. The Tenant is an industry leader in combination drug delivery and manufacturing and provides expertise at every stage of pulmonary and nasal, injectable, and transdermal therapy development and manufacturing. The Tenant’s offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. The Tenant serves a global client base from its nine manufacturing, research, and development facilities located in the United States and United Kingdom.

Offering documents 6

Projected distributions are the sponsor's estimates of annual cash flow on invested equity. They are not guaranteed, may change or stop, and may include a return of capital. LTV is the offering's debt divided by its total capitalization. Information reflects my offering records as of October 28, 2026 and may have changed. This page is not an offer to sell or a solicitation of an offer to buy any security; offers are made only through the offering documents to eligible investors.

More industrial offerings